secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortress Biotech, Inc. (FBIO)
CIK:        0001429260
Form:       8-K
Filed at:   2025-11-17T23:59:59+00:00
Accession:  0001104659-25-112945
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Fortress Biotech's majority-owned Cyprium gets NDA resubmission for CUTX-101 to FDA
--------------------------------------------------------------------------------

- Sentynl resubmitted NDA for CUTX-101 to FDA on Nov 14, 2025.
- Prior Complete Response Letter on Oct 1, 2025.
- Cyprium retains ownership of any Priority Review Voucher upon approval.
- Cyprium eligible for up to $129M in development and sales milestones plus royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429260/000110465925112945/0001104659-25-112945-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429260/000110465925112945/tm2531443d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-112945

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer